Can Axitinib treat advanced kidney cancer?

Axitinib (Axitinib) is a targeted therapy approved for the treatment of advanced renal cell carcinoma (RCC, kidney cancer). Renal cell carcinoma is a relatively common urinary system tumor, while advanced kidney cancer refers to kidney cancer that has spread to other tissues or organs.

Axitinib's mechanism of action primarily involves inhibiting the vascular endothelial growth factor receptor (VEGFR), a receptor closely related to angiogenesis and new blood vessel formation. By blocking VEGFR, axitinib weakens the tumor's dependence on the blood supply, slowing its growth and spread.

Research in clinical trials and practical applications has shown that axitinib shows good efficacy in the treatment of patients with advanced renal cancer. It is often used as one of the first-line or second-line treatment options, especially for patients whose disease has progressed after receiving immunotherapy or other targeted therapies.

The therapeutic effect of axitinib can be reflected by slowing disease progression, prolonging survival and improving patients' quality of life. During the treatment process, doctors usually make adjustments based on the patient's specific situation and drug tolerance to achieve the best therapeutic effect.

Axitinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price of 5mg*28 tablets is about 5,000 to 6,000 yuan. For specific prices, please consult the local hospital pharmacy. There are original and generic axitinib drugs abroad. The original drug is Pfizer's original drug, and the price is about 6,000 yuan; the generic drugs are mainly Bangladeshi generics and Indian generics. The price of Bangladeshi generics in 5mg*60 tablets is more than 1,000 yuan, and the price of Indian generics is around a few hundred yuan. The ingredients of original drugs and generic drugs are basically the same.